Advanced Search

National Health (Paraplegic and Quadriplegic Program) Special Arrangement Amendment Instrument 2012 (No. 2) (No. PB 91 of 2012)

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now for only USD$40 per month.
PB 91 of 2012
National Health (Paraplegic and Quadriplegic Program) Special Arrangement Amendment Instrument 2012 (No.2)[1]
National Health Act 1953
I, KIM BESSELL, First Assistant Secretary (Acting), Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this Instrument under subsections 100(1) and (2) of the National Health Act 1953.
Dated         27  September  2012
 
 
 
 
 
 
 
 
 
 
 
KIM BESSELL
First Assistant Secretary (Acting)
Pharmaceutical Benefits Division
Department of Health and Ageing
 
1       Name of Instrument
(1)          This Instrument is the National Health (Paraplegic and Quadriplegic Program) Special Arrangement Amendment Instrument 2012 (No.2).
(2)          This Instrument may also be cited as PB 91 of 2012.
2       Commencement
This Instrument commences on 1 October 2012.
3       Amendments to National Health (Paraplegic and Quadriplegic Program) Special Arrangement 2010
Schedule 1 amends the National Health (Paraplegic and Quadriplegic Program) Special Arrangement 2010 (PB 118 of 2010)
 
.
Schedule 1     Amendments
                                      Section 3
 
[1]           Section 3, Note
 
Omit:
·     approved price to pharmacists
 
Insert (in alphabetical order):
·     approved ex-manufacturer price
·     claimed price
·     pack quantity
·     proportional ex-manufacturer price
 
[2]           Omit section 8
 
[3]           Subsection 14(1)
Insert after ‘supplies’:
a pack quantity of
 
[4]           Subsection 14(2)
Omit the subsection.
 
Insert:
(2)        For subsection (1), the amount is:
(a)     if there is no claimed price for the pack quantity of the pharmaceutical benefit:
(i)      the price to pharmacists for the pack quantity worked out under the determination under paragraph 98B(1)(a) of the Act; and
(ii)     a handling fee of 2.75% of that amount; or
(b)     if there is a claimed price for the pack quantity of the pharmaceutical benefit:
(i)      the claimed price for the pack quantity  plus a wholesale mark-up calculated in accordance with subsection (3); and
(ii)     a handling fee of 2.75% of that amount.
(3)        For paragraph (2)(b), the wholesale mark‑up for the pack quantity of the pharmaceutical benefit is to be worked out using the methodology for calculating the wholesale mark-up for ready-prepared pharmaceutical benefits in the determination under paragraph 98B(1)(a) of the Act, subject to the following:
(a)     for the purposes of identifying the appropriate wholesale mark-up formula in Step 2 of the methodology, the ex-manufacturer price for the relevant quantity is to be worked out proportionately from the approved ex‑manufacturer price or proportional ex-manufacturer price for the pack quantity of the pharmaceutical benefit; and
(b)     otherwise, the methodology is to be applied as if the claimed price for the pack quantity of the pharmaceutical benefit were the approved ex‑manufacturer price or proportional ex‑manufacturer price for the pack quantity.
 
[5]       Schedule 1
Omit the Schedule.
 
Insert:
 
Schedule 1     Pharmaceutical benefits covered by this Special Arrangement and related information
(sections 4, 6 and 11)
 
Listed Drug
Form
Manner of Administration
Brand
Responsible Person
Maximum Amount
 

 
 
 
 
 
 
 

 
 
 
 
 
 
 

Bisacodyl
Tablet, 5mg
oral
Bisalax
AS
400
 

 
 
 
Lax‑Tab
AE
400
 
 

 
Suppositories 10mg, 10
rectal
Dulcolax
BY
9
 

 
 
 
Petrus Bisacodyl Suppositories
PP
9
 

 
Suppositories 10mg, 12
rectal
Petrus Bisacodyl Suppositories
PP
8
 

 
Enemas 10mg in 5mL, 25
rectal
Bisalax
AS
2
 

 
 
 
 
 
 
 

 
 
 
 
 
 
 

 
 
 
 
 
 
 

Glycerol
Suppositories 700mg, 12
rectal
Petrus Pharmaceuticals Pty Ltd
PP
8
 

 
Suppositories, 1.4g, 12
rectal
Petrus Pharmaceuticals Pty Ltd
PP
8
 

 
Suppositories 2.8g, 12
rectal
Petrus Pharmaceuticals Pty Ltd
PP
8
 

Macrogol 3350
Sachets containing powder for oral solution 13.125g with electrolytes, 30
oral
Movicol
NE
2
 

Sorbitol with Sodium Citrate and Sodium Lauryl Sulfoacetate
Enemas 3.125g‑450mg‑45mg in 5mL, 12
rectal
Micolette
AE
4
 

 
 
 
Microlax
JT
4
 

Sterculia with Frangula Bark
Granules 620mg‑80mg, per g, 500g
oral
Normacol Plus
NE
2
 


[1] Note  All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003.See http://www.frli.gov.au